Oppenheimer Reiterates Perform on AN2 Therapeuticsto Perform
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated a Perform rating on AN2 Therapeutics (NASDAQ:ANTX), maintaining the company's current stock performance outlook.
April 01, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Jeff Jones reiterates a Perform rating on AN2 Therapeutics, indicating no change in the stock's performance outlook.
The reiteration of a Perform rating by a prominent analyst suggests that there are no immediate catalysts expected to significantly change the stock's trajectory in the short term. This stability is reflected in the neutral score.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 90